Eva M Ciruelos(@evaciruelos) 's Twitter Profileg
Eva M Ciruelos

@evaciruelos

Medical Oncologist, Breast Cancer Unit, Hospital 12 Octubre and HM Hospitales, Madrid. CoChair at SOLTI Group in cancer research. #breastcancer #beSOLTI

ID:2390631678

calendar_today15-03-2014 08:06:16

677 Tweets

1,1K Followers

218 Following

Eva M Ciruelos(@evaciruelos) 's Twitter Profile Photo

SOLTI impulsa su estrategia de desarrollo de negocio con la incorporación de Ramón Mel a su equipo directivo ⁦SOLTI #cancerresearch⁩ ⁦Ramon Mel⁩ gruposolti.org/solti-impulsa-…

account_circle
Eva M Ciruelos(@evaciruelos) 's Twitter Profile Photo

Pacientes y profesionales sanitarios a favor de humanizar la asistencia sanitaria del cancer de la mujer lavanguardia.com/sociedad/20240…

account_circle
Eva M Ciruelos(@evaciruelos) 's Twitter Profile Photo

Oncología Médica | Hospital Universitario 12 de Octubre. Want to know our team? Visit us at
SEOM⁩ ⁦SOLTI #cancerresearch⁩ ⁦ESMO Open⁩ ⁦OncoAlert⁩ ⁦Diario Médico⁩ comunidad.madrid/hospital/12oct…

account_circle
Eva M Ciruelos(@evaciruelos) 's Twitter Profile Photo

ER+ HER2- PIK3 mut BC patients who relapse during adjuvant therapy : impressive benefit of the addition of inavolisib to standard fulvestrant + palbo SOLTI #cancerresearch OncoAlert ESMO Open SABCS The ASCO Post

ER+ HER2- PIK3 mut BC patients who relapse during adjuvant therapy : impressive benefit of the addition of inavolisib to standard fulvestrant + palbo #SABCS23 @_SOLTI @OncoAlert @ESMO_Open @SABCSSanAntonio @ASCOPost
account_circle
Sara Tolaney(@stolaney1) 's Twitter Profile Photo

MONARCH3: AI +/- abemaciclib
Final OS analysis
Median follow-up 8.1 years

66.8 vs 53.7 mo
Absolute Difference 13.1 mo
Not statistically significant

23.3% progression free at 6 yrs on the abemaciclib arm

@oncolaert

account_circle